Product Description
BOS161721(avizakimab) is a fully human anti-IL-21 antibody
Mechanisms of Action: IL21 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boston Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Lupus Erythematosus, Systemic
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Healthy Volunteers |
2021-06-04 |
|
| 2018-000305-23 | P2 |
Completed |
Lupus Erythematosus, Systemic |
2020-11-26 |
|
| BOS161721-02 | P2 |
Completed |
Lupus Erythematosus, Systemic |
2020-11-26 |
|
| BOS161721-01 | P1 |
Completed |
Healthy Volunteers |
2018-04-27 |
27% |